- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Dexcom stock drops 40% after reporting CGM sales challenges | ||
| Fr | BMS axes multiple myeloma bispecific months after filing to run phase 3 trial | ||
| Fr | Acticor halts phase 2/3 stroke trial for blood thinner over futility | ||
| Fr | Calliditas' liver disease trial hits primary endpoint after sweeping changes to design | ||
| Fr | Cue lays off 25%, prioritizing preclinical autoimmune assets over clinical-stage cancer drugs | ||
| Do | In Eisai, Medidata finds its first big buyer for new clinical trial management platform | ||
| Do | Abbott offers FreeStyle Libre 3 sensor replacements due to inaccurate glucose readings | ||
| Do | Mirati's Charles Baum takes the helm at Terremoto Biosciences | ||
| Do | Edwards Lifesciences inks $1.6B in acquisition deals for JenaValve, Endotronix | ||
| Do | AbbVie axes midstage Alzheimer's program amid 'evolving landscape' | ||
| Do | Chemomab trumpets liver disease win, but investors retreat | ||
| Do | Viking's obesity med set to charge into phase 3, with $300M earmarked for clinical program | ||
| Do | Sanofi drops phase 2 dwarfism drug as part of rare disease clear-out | ||
| Do | Roche pumps brakes in Pompe disease, axing gene therapy after assessing competition | ||
| Mi | Autobahn Labs partners with Charles River to speed translation of academic research | ||
| Mi | Novartis hopes for better luck with bispecifics via $150M upfront Dren Bio deal | ||
| Mi | Boston Scientific sees electric 125% EP growth after pulsed field ablation launch | ||
| Mi | Tourette's biotech Asarina to wind down after outreach to 200 companies fails to produce a partner | ||
| Mi | Pfizer's gene therapy offers alternative to 'burden' of regular infusions, but can it outlast Roctavian? | ||
| Mi | OSE, flying solo after Servier split, suggests symptom improvements for ulcerative colitis prospect | ||
| Mi | Biogen, Sage fail midphase essential tremor trial, extending long wait for new option | ||
| Mi | Cancer-focused Actuate makes second tweak to IPO plans in a week | ||
| Di | Insilico Medicine launches AI assistant for drafting medical research papers | ||
| Di | AstraZeneca plants an EGFR tree with Pinetree deal worth $45M | ||
| Di | Moderna co-founder Robert Langer is leaving the vaccine pioneer's board |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
